Printer Friendly

NEORX RECEIVES ALPHA-EMITTER LINKING PATENT

 NEORX RECEIVES ALPHA-EMITTER LINKING PATENT
 SEATTLE, April 13 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX)


announced today that it received a U.S. patent covering methods of linking the alpha-emitter astatine-211 to form radiopharmaceutical compounds. Alpha-emitters have been estimated to deliver up to 400 times the energy of beta-emitting radionuclides (such as yttrium-90 and rhenium-186) that are currently being used in the targeted therapy of cancer.
 "This patent adds to our proprietary protection for chemicals that link various forms of radioactivity stably to targeting molecules," said Alan Fritzberg, Ph.D., NeoRx's chief scientific officer. "Because of the high energy of alpha particles, it is particularly important that the radioisotope be firmly linked to the targeting molecule. Alpha- emitters have attractive properties for targeted therapy including short particle length that maximizes toxicity to normal surrounding cells, and high energy that maximizes the potential for killing target cells even in areas of tumors that are not well oxygenated. In addition, because of their short half-lives, they are well suited for use with our recently acquired pre-targeting technology."
 NeoRx scientists have linked astatine to antibodies and have demonstrated the stability of the resulting conjugate in animal studies. NeoRx is currently seeking a corporate collaborator to support the development of astatine-based targeted cancer therapy.
 NeoRx Corporation develops targeted biopharmaceutical products to detect and treat diseases, with an initial focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA for two OncoTrac(R) cancer imaging products and has completed a phase III trial for a third. Targeted biopharmaceuticals to treat cancer, restenosis after angioplasty and autoimmune diseases are in pre-clinical testing.
 -0- 4/13/92
 /CONTACT: Robert M. Littauer, vice president, CFO and treasurer of NeoRx, 206-286-2519; or Anthony J. Russo or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation ST: Washington IN: MTC SU:


TQ-TS -- NY019 -- 7620 04/13/92 09:43 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 13, 1992
Words:323
Previous Article:SOUTHTRUST ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
Next Article:PRESIDENT GEORGE BUSH TO VISIT GIDDINGS & LEWIS PLANT IN FRASER, MICH.


Related Articles
NEORX RECEIVES $9 MILLION FROM DAVID BLECH
NEORX ACQUIRES PRE-TARGETING TECHNOLOGY FROM STANFORD UNIVERSITY
NEORX REPORTS BENEFITS OF LUNG CANCER IMAGING PRODUCTS AND STATUS OF CANCER THERAPY DEVELOPMENT PROGRAM
NEORX AWARDED PATENT FOR IMPROVED RADIOLABELING COMPOUNDS FOR CANCER IMAGING AND THERAPY
NEORX TO GRANT LICENSE FOR RHENIUM CANCER THERAPY TO STERLING WINTHROP AS PART OF A $10 MILLION AGREEMENT
NEORX ANNOUNCES ENHANCED TUMOR DOSE FROM PRE-TARGETING IN PRECLINICAL MODELS
NEORX APPOINTS JOHN RENO AS VICE PRESIDENT, RESEARCH & DEVELOPMENT
NEORX DEMONSTRATES EFFICACY IN ANIMALS OF TWO THERAPEUTIC PRODUCT LINES
NEORX PROMOTES JEFFREY MILLER TO SENIOR VICE PRESIDENT
NEORX DEFEATS IMMUNOMEDICS' ATTEMPT TO DISMISS PATENT INFRINGEMENT SUIT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters